hydroxychloroquine has been researched along with Arrhythmia in 58 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine (HCQ) is widely used to treat rheumatic diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS)." | 8.02 | Hydroxychloroquine Does Not Increase the Risk of Cardiac Arrhythmia in Common Rheumatic Diseases: A Nationwide Population-Based Cohort Study. ( Chan, KC; Li, LC; Lo, CH; Lo, TH; Su, CH; Tsai, CF; Wang, YH; Wei, JC, 2021) |
| "Hydroxychloroquine (HCQ) may prolong the QT interval, a risk factor for torsade de pointes, a potentially fatal ventricular arrhythmia." | 8.02 | Cardiovascular Safety of Hydroxychloroquine in US Veterans With Rheumatoid Arthritis. ( Ahmed, A; Arundel, C; Boehm, D; Cheng, Y; Connell, LB; Faselis, C; Fletcher, RD; Fonarow, GC; Heimall, MS; Karasik, PE; Kerr, GS; Liappis, AP; Moore, HJ; Nashel, DJ; Redd, DF; Shao, Y; Sheriff, HM; Taub, DD; Weintrob, AC; Zeng-Treitler, Q; Zhang, S, 2021) |
| "In patients with systemic lupus erythematosus, hydroxychloroquine treatment did not significantly increase the risk of cardiac arrhythmia or life-threatening ventricular arrhythmia regardless of the different hydroxychloroquine treatment duration, drug adherence rate, or daily dose." | 8.02 | Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study. ( Chan, KC; Li, LC; Lo, CH; Lo, TH; Su, CH; Tsai, CF; Wang, YH; Wei, JC, 2021) |
| "Also, no malignant ventricular arrhythmia or death secondary to ventricular arrhythmia occurred during the treatment in both groups." | 5.62 | Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19. ( Bilge, AR; Çetin, N; Gündüz, R; Özdemir, İH; Özen, MB; Özlek, B, 2021) |
| " In fact, two of the actually used drugs against SARS-CoV2, such as chloroquine and the combination lopinavir/ritonavir, might determine a QT (the time from the start of the Q wave to the end of the T wave) interval prolongation and they show several interactions with antiarrhythmic drugs and antipsychotic medications, making them prone to an increased risk of developing arrhythmias." | 5.12 | COVID-19 and the burning issue of drug interaction: never forget the ECG. ( Cameli, M; Cameli, P; Franchi, F; Mandoli, GE; Menci, D; Mondillo, S; Sciaccaluga, C; Sisti, N; Valente, S, 2021) |
| "We applied a set of in silico and in vitro assays, compliant with the Comprehensive In Vitro Proarrhythmia Assay (CiPA) paradigm, to assess the risk of chloroquine (CLQ) or hydroxychloroquine (OH-CLQ)-mediated QT prolongation and Torsades de Pointes (TdP), alone and combined with erythromycin (ERT) and azithromycin (AZI), drugs repurposed during the first wave of coronavirus disease 2019 (COVID-19)." | 4.02 | Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off-label in the first wave of COVID-19. ( Abernathy, M; Anderson, WD; Beattie, KA; Chaudhary, KW; Coulot, J; Delaunois, A; Gryshkova, V; Hebeisen, S; Holbrook, M; Kramer, J; Kuryshev, Y; Leishman, D; Lushbough, I; Passini, E; Redfern, WS; Rodriguez, B; Rossman, EI; Trovato, C; Valentin, JP; Wu, C, 2021) |
| " We report on a chronic preclinical drug screening platform, a cardiac microphysiological system (MPS), to assess cardiotoxicity associated with repurposed hydroxychloroquine (HCQ) and azithromycin (AZM) polytherapy in a mock phase I safety clinical trial." | 4.02 | In vitro safety "clinical trial" of the cardiac liability of drug polytherapy. ( Charrez, B; Charwat, V; Edwards, AG; Finsberg, H; Healy, KE; Miller, EW; Siemons, B, 2021) |
| "Hydroxychloroquine (HCQ) is widely used to treat rheumatic diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS)." | 4.02 | Hydroxychloroquine Does Not Increase the Risk of Cardiac Arrhythmia in Common Rheumatic Diseases: A Nationwide Population-Based Cohort Study. ( Chan, KC; Li, LC; Lo, CH; Lo, TH; Su, CH; Tsai, CF; Wang, YH; Wei, JC, 2021) |
| "Hydroxychloroquine (HCQ) may prolong the QT interval, a risk factor for torsade de pointes, a potentially fatal ventricular arrhythmia." | 4.02 | Cardiovascular Safety of Hydroxychloroquine in US Veterans With Rheumatoid Arthritis. ( Ahmed, A; Arundel, C; Boehm, D; Cheng, Y; Connell, LB; Faselis, C; Fletcher, RD; Fonarow, GC; Heimall, MS; Karasik, PE; Kerr, GS; Liappis, AP; Moore, HJ; Nashel, DJ; Redd, DF; Shao, Y; Sheriff, HM; Taub, DD; Weintrob, AC; Zeng-Treitler, Q; Zhang, S, 2021) |
| "In patients with systemic lupus erythematosus, hydroxychloroquine treatment did not significantly increase the risk of cardiac arrhythmia or life-threatening ventricular arrhythmia regardless of the different hydroxychloroquine treatment duration, drug adherence rate, or daily dose." | 4.02 | Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study. ( Chan, KC; Li, LC; Lo, CH; Lo, TH; Su, CH; Tsai, CF; Wang, YH; Wei, JC, 2021) |
| " This document attempts to provide reasonable guidance for the use of antimicrobials which have uncertain benefit but may increase risk of QT interval prolongation and ventricular proarrhythmia, notably, chloroquine, hydroxychloroquine, azithromycin, and lopinavir/ritonavir." | 3.96 | Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society. ( Alqarawi, W; Healey, JS; Krahn, AD; Laksman, Z; MacIntyre, CJ; Roberts, JD; Sapp, JL; Steinberg, C; Tadros, R, 2020) |
| "There is limited data regarding the electrophysiological abnormalities and arrhythmias in children with COVID-19, including those associated with treatment using potentially proarrhythmic hydroxychloroquine (HCQ) and azithromycin (AZN)." | 3.96 | Incidence of arrhythmias and electrocardiographic abnormalities in symptomatic pediatric patients with PCR-positive SARS-CoV-2 infection, including drug-induced changes in the corrected QT interval. ( Blaufox, AD; Friedman, RA; Ganigara, M; Mitchell, E; Samuel, S; Schleien, C; Sharma, C, 2020) |
| "Torsades de pointes (TdP) and sudden cardiac death (SCD) were reported." | 2.72 | Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review. ( Amarasekera, AT; Kayes, T; Kodsi, M; MacIntyre, CR; Malaty, M; Tan, TC, 2021) |
| " However, some of these medications have potential cardiac adverse effects." | 2.66 | Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol. ( Lazar, S; Naksuk, N; Peeraphatdit, TB, 2020) |
| "The novel coronavirus disease 2019, otherwise known as COVID-19, is a global pandemic with primary respiratory manifestations in those who are symptomatic." | 2.66 | Approach to Acute Cardiovascular Complications in COVID-19 Infection. ( Abdalla, M; Anstey, DE; Fried, JA; Givens, RC; Karmpaliotis, D; Kirtane, AJ; Kodali, SK; Kumaraiah, D; Leon, MB; Masoumi, A; Rabbani, LE; Ranard, LS; Sayer, G; Schwartz, A; Takeda, K; Uriel, N, 2020) |
| "Hydroxychloroquine (HCQ) is a derivative of the antimalaria drug chloroquine primarily prescribed for autoimmune diseases." | 1.72 | In vitro ion channel profile and ex vivo cardiac electrophysiology properties of the R(-) and S(+) enantiomers of hydroxychloroquine. ( Angouillant-Boniface, O; Ballet, V; Bohme, GA; Boukaiba, R; Brohan, E; Carriot, T; Chambard, JM; Chantoiseau, C; Fouconnier, S; Houtmann, S; Partiseti, M; Prévost, C; Schio, L; Schombert, B, 2022) |
| "We identified 3302 adverse event reports from the FAERS database in the year 2020 and divided them into COVID-19 and non-COVID-19 groups, respectively." | 1.72 | An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19. ( Li, Y; Luo, M; Wu, B; Wu, F, 2022) |
| "Also, no malignant ventricular arrhythmia or death secondary to ventricular arrhythmia occurred during the treatment in both groups." | 1.62 | Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19. ( Bilge, AR; Çetin, N; Gündüz, R; Özdemir, İH; Özen, MB; Özlek, B, 2021) |
| "Hydroxychloroquine was prematurely discontinued in 1." | 1.62 | Medication safety in a pandemic: A multicentre point prevalence study of QTc monitoring of hydroxychloroquine for COVID-19. ( Daniel, NM; Gerges, J; Leach, H; Leonida, N; Patel, A; Patel, G; Patel, V; Raja, K; Shah, M; Smoke, SM, 2021) |
| "In the largest reported cohort of coronavirus disease 2019 patients to date treated with chloroquine/hydroxychloroquine±azithromycin, no instances of Torsade de pointes, or arrhythmogenic death were reported." | 1.56 | Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection. ( Beldner, S; Chang, D; Chinitz, J; Epstein, LM; Gabriels, J; Goldner, B; Ismail, H; John, R; Mahmood, E; Makker, P; Mansoor, A; Mitra, R; Mountantonakis, S; Saleh, M; Skipitaris, N; Soo Kim, B; Willner, J, 2020) |
| "Secondary outcomes were cardiac arrest and abnormal electrocardiogram findings (arrhythmia or QT prolongation)." | 1.56 | Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State. ( Blog, DS; DeHovitz, J; Dufort, EM; Holtgrave, DR; Hutton, B; Kirkwood, J; Kumar, J; Muse, A; Rosenberg, ES; Tesoriero, J; Udo, T; Weinberg, P; Wilberschied, LA; Zucker, HA, 2020) |
| "Among candidate drugs to treat coronavirus disease 2019 (COVID-19), the combination of hydroxychloroquine (HCQ) and azithromycin (AZ) has received intense worldwide attention." | 1.56 | Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection. ( Azria, P; Borie, MF; Guillerm, JC; Hubert, S; Lorc'h, EL; Mahé, A; Ménage, E; Mourad, JJ; Voisin, O, 2020) |
| "HCQ administration is safe for a short-term treatment for patients with COVID-19 infection regardless of the clinical setting of delivery, causing only modest QTc prolongation and no directly attributable arrhythmic deaths." | 1.56 | Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings. ( Antinori, S; Bellia, A; Biffi, M; Busana, M; Casalini, G; Cogliati, CB; Duru, F; Fabbricatore, D; Forleo, GB; Galiè, N; Galli, M; Gasperetti, A; Lanfranchi, A; Lavalle, C; Mariani, MV; Mitacchione, G; Saguner, A; Salghetti, F; Schiavone, M; Tocci, M; Tondo, C; Viale, P; Ziacchi, M, 2020) |
| " For the lack of efficacy, we discuss the fundamental differences of treatment initiation between in vitro and in vivo studies, the pitfalls of the pharmacological calculations of effective blood drug concentrations and related dosing regimens, and the possible negative effect of HCQ on the antiviral type-I interferon response." | 1.56 | It is time to drop hydroxychloroquine from our COVID-19 armamentarium. ( Kashour, T; Tleyjeh, IM, 2020) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (3.45) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (1.72) | 29.6817 |
| 2010's | 1 (1.72) | 24.3611 |
| 2020's | 54 (93.10) | 2.80 |
| Authors | Studies |
|---|---|
| Thomet, U | 1 |
| Amuzescu, B | 1 |
| Knott, T | 1 |
| Mann, SA | 1 |
| Mubagwa, K | 1 |
| Radu, BM | 1 |
| Ballet, V | 1 |
| Bohme, GA | 1 |
| Brohan, E | 1 |
| Boukaiba, R | 1 |
| Chambard, JM | 1 |
| Angouillant-Boniface, O | 1 |
| Carriot, T | 1 |
| Chantoiseau, C | 1 |
| Fouconnier, S | 1 |
| Houtmann, S | 1 |
| Prévost, C | 1 |
| Schombert, B | 1 |
| Schio, L | 1 |
| Partiseti, M | 1 |
| Mazaherpour, H | 1 |
| Sofian, M | 1 |
| Farahani, E | 1 |
| Abdi, A | 1 |
| Mazaherpour, S | 1 |
| Bavand, A | 1 |
| Ramezani, A | 1 |
| Zhu, X | 1 |
| Wang, Y | 1 |
| Xiao, Y | 1 |
| Gao, Q | 1 |
| Gao, L | 1 |
| Zhang, W | 1 |
| Xin, X | 1 |
| Chen, K | 1 |
| Srivastava, U | 1 |
| Ginjupalli, VKM | 1 |
| Cupelli, M | 1 |
| Lazzerini, PE | 1 |
| Capecchi, PL | 1 |
| Chen, L | 1 |
| Boutjdir, M | 1 |
| Schiavone, M | 2 |
| Gasperetti, A | 2 |
| Gherbesi, E | 1 |
| Bergamaschi, L | 1 |
| Arosio, R | 1 |
| Mitacchione, G | 2 |
| Viecca, M | 1 |
| Forleo, GB | 2 |
| Solow, EB | 1 |
| Bermas, BL | 1 |
| Luo, M | 1 |
| Wu, B | 1 |
| Li, Y | 1 |
| Wu, F | 1 |
| Braunstein, ED | 3 |
| Olshan, DS | 3 |
| Gabriels, JK | 3 |
| Shaikh, Z | 3 |
| Lerman, BB | 3 |
| Cheung, JW | 3 |
| Desmarais, J | 1 |
| Rosenbaum, JT | 1 |
| Link, M | 1 |
| Kovacs, R | 1 |
| Souza-Silva, MVR | 1 |
| Pereira, DN | 1 |
| Pires, MC | 1 |
| Vasconcelos, IM | 1 |
| Schwarzbold, AV | 1 |
| Vasconcelos, DH | 1 |
| Pereira, EC | 1 |
| Manenti, ERF | 1 |
| Costa, FR | 1 |
| Aguiar, FC | 1 |
| Anschau, F | 1 |
| Bartolazzi, F | 1 |
| Nascimento, GF | 1 |
| Vianna, HR | 1 |
| Batista, JDL | 1 |
| Machado-Rugolo, J | 1 |
| Ruschel, KB | 1 |
| Ferreira, MAP | 1 |
| Oliveira, LS | 1 |
| Menezes, LSM | 1 |
| Ziegelmann, PK | 1 |
| Tofani, MGT | 1 |
| Bicalho, MAC | 1 |
| Nogueira, MCA | 1 |
| Guimarães-Júnior, MH | 1 |
| Aguiar, RLO | 1 |
| Rios, DRA | 1 |
| Polanczyk, CA | 1 |
| Marcolino, MS | 1 |
| Roden, DM | 1 |
| Harrington, RA | 1 |
| Poppas, A | 1 |
| Russo, AM | 1 |
| Juurlink, DN | 1 |
| Sapp, JL | 1 |
| Alqarawi, W | 1 |
| MacIntyre, CJ | 1 |
| Tadros, R | 1 |
| Steinberg, C | 1 |
| Roberts, JD | 1 |
| Laksman, Z | 1 |
| Healey, JS | 1 |
| Krahn, AD | 1 |
| Lentini, G | 1 |
| Cavalluzzi, MM | 1 |
| Habtemariam, S | 1 |
| Chang, D | 2 |
| Saleh, M | 2 |
| Gabriels, J | 2 |
| Ismail, H | 2 |
| Goldner, B | 2 |
| Willner, J | 2 |
| Beldner, S | 2 |
| Mitra, R | 2 |
| John, R | 2 |
| Epstein, LM | 2 |
| Soo Kim, B | 1 |
| Mansoor, A | 1 |
| Mahmood, E | 1 |
| Makker, P | 1 |
| Chinitz, J | 1 |
| Skipitaris, N | 1 |
| Mountantonakis, S | 1 |
| Monzani, A | 1 |
| Genoni, G | 1 |
| Scopinaro, A | 1 |
| Pistis, G | 1 |
| Kozel, D | 1 |
| Secco, GG | 1 |
| Naksuk, N | 1 |
| Lazar, S | 1 |
| Peeraphatdit, TB | 1 |
| Rosenberg, ES | 1 |
| Dufort, EM | 1 |
| Udo, T | 1 |
| Wilberschied, LA | 1 |
| Kumar, J | 1 |
| Tesoriero, J | 1 |
| Weinberg, P | 1 |
| Kirkwood, J | 1 |
| Muse, A | 1 |
| DeHovitz, J | 1 |
| Blog, DS | 1 |
| Hutton, B | 1 |
| Holtgrave, DR | 1 |
| Zucker, HA | 1 |
| Everaert, BR | 1 |
| Muylle, J | 1 |
| Bartholomeus Twickler, T | 1 |
| Asensio, E | 1 |
| Acunzo, R | 1 |
| Uribe, W | 1 |
| Saad, EB | 1 |
| Sáenz, LC | 1 |
| Graef, ER | 1 |
| Liew, JW | 1 |
| Kim, AH | 1 |
| Sparks, JA | 1 |
| Erre, GL | 1 |
| Ferraccioli, ES | 1 |
| Piga, M | 1 |
| Mangoni, A | 1 |
| Passiu, G | 1 |
| Gremese, E | 1 |
| Ferraccioli, G | 1 |
| Chorin, E | 1 |
| Dai, M | 1 |
| Shulman, E | 1 |
| Wadhwani, L | 1 |
| Bar-Cohen, R | 1 |
| Barbhaiya, C | 1 |
| Aizer, A | 1 |
| Holmes, D | 1 |
| Bernstein, S | 1 |
| Spinelli, M | 1 |
| Park, DS | 1 |
| Chinitz, LA | 1 |
| Jankelson, L | 1 |
| Servick, K | 1 |
| Enserink, M | 1 |
| Ranard, LS | 1 |
| Fried, JA | 1 |
| Abdalla, M | 1 |
| Anstey, DE | 1 |
| Givens, RC | 1 |
| Kumaraiah, D | 1 |
| Kodali, SK | 1 |
| Takeda, K | 1 |
| Karmpaliotis, D | 1 |
| Rabbani, LE | 1 |
| Sayer, G | 1 |
| Kirtane, AJ | 1 |
| Leon, MB | 1 |
| Schwartz, A | 1 |
| Uriel, N | 1 |
| Masoumi, A | 1 |
| Medeiros-Domingo, A | 1 |
| Carrasco, OF | 1 |
| Berni-Betancourt, A | 1 |
| Samuel, S | 1 |
| Friedman, RA | 1 |
| Sharma, C | 1 |
| Ganigara, M | 1 |
| Mitchell, E | 1 |
| Schleien, C | 1 |
| Blaufox, AD | 1 |
| Offerhaus, JA | 1 |
| Wilde, AAM | 1 |
| Remme, CA | 1 |
| Stremmel, C | 1 |
| Kellnar, A | 1 |
| Massberg, S | 1 |
| Kääb, S | 1 |
| Capucci, A | 1 |
| Santarelli, A | 1 |
| Bartolomei, M | 1 |
| Paolizzi, C | 1 |
| Biagetti, C | 1 |
| Dappozzo, A | 1 |
| Piovaccari, G | 1 |
| Voisin, O | 1 |
| Lorc'h, EL | 1 |
| Mahé, A | 1 |
| Azria, P | 1 |
| Borie, MF | 1 |
| Hubert, S | 1 |
| Ménage, E | 1 |
| Guillerm, JC | 1 |
| Mourad, JJ | 1 |
| Norinder, U | 1 |
| Tuck, A | 1 |
| Norgren, K | 1 |
| Munic Kos, V | 1 |
| Sciaccaluga, C | 1 |
| Cameli, M | 1 |
| Menci, D | 1 |
| Mandoli, GE | 1 |
| Sisti, N | 1 |
| Cameli, P | 1 |
| Franchi, F | 1 |
| Mondillo, S | 1 |
| Valente, S | 1 |
| Hummel, JP | 2 |
| Akar, JG | 2 |
| Maraj, I | 1 |
| Taoutel, R | 1 |
| Chamoun, R | 1 |
| Workman, VK | 1 |
| Tran, L | 1 |
| Abboud, JM | 1 |
| Afif, C | 1 |
| Chouairi, S | 1 |
| Delvecchio, A | 1 |
| Howes, CJ | 1 |
| Enriquez, AD | 1 |
| Biffi, M | 1 |
| Duru, F | 1 |
| Ziacchi, M | 1 |
| Lavalle, C | 1 |
| Saguner, A | 1 |
| Lanfranchi, A | 1 |
| Casalini, G | 1 |
| Tocci, M | 1 |
| Fabbricatore, D | 1 |
| Salghetti, F | 1 |
| Mariani, MV | 1 |
| Busana, M | 1 |
| Bellia, A | 1 |
| Cogliati, CB | 1 |
| Viale, P | 1 |
| Antinori, S | 1 |
| Galli, M | 1 |
| Galiè, N | 1 |
| Tondo, C | 1 |
| Malaty, M | 1 |
| Kayes, T | 1 |
| Amarasekera, AT | 1 |
| Kodsi, M | 1 |
| MacIntyre, CR | 1 |
| Tan, TC | 1 |
| Paul, M | 1 |
| Kashour, T | 1 |
| Tleyjeh, IM | 1 |
| Alkasir, A | 1 |
| Lippmann, S | 1 |
| Özdemir, İH | 1 |
| Özlek, B | 1 |
| Özen, MB | 1 |
| Gündüz, R | 1 |
| Çetin, N | 1 |
| Bilge, AR | 1 |
| Maille, B | 1 |
| Wilkin, M | 1 |
| Million, M | 1 |
| Rességuier, N | 1 |
| Franceschi, F | 1 |
| Koutbi-Franceschi, L | 1 |
| Hourdain, J | 1 |
| Martinez, E | 1 |
| Zabern, M | 1 |
| Gardella, C | 1 |
| Tissot-Dupont, H | 1 |
| Singh, JP | 1 |
| Deharo, JC | 1 |
| Fiorina, L | 1 |
| Ehrlich, H | 1 |
| Elkbuli, A | 1 |
| Delaunois, A | 1 |
| Abernathy, M | 1 |
| Anderson, WD | 1 |
| Beattie, KA | 1 |
| Chaudhary, KW | 1 |
| Coulot, J | 1 |
| Gryshkova, V | 1 |
| Hebeisen, S | 1 |
| Holbrook, M | 1 |
| Kramer, J | 1 |
| Kuryshev, Y | 1 |
| Leishman, D | 1 |
| Lushbough, I | 1 |
| Passini, E | 1 |
| Redfern, WS | 1 |
| Rodriguez, B | 1 |
| Rossman, EI | 1 |
| Trovato, C | 1 |
| Wu, C | 1 |
| Valentin, JP | 1 |
| Eftekhar, SP | 1 |
| Kazemi, S | 1 |
| Barary, M | 1 |
| Javanian, M | 1 |
| Ebrahimpour, S | 1 |
| Ziaei, N | 1 |
| Charrez, B | 1 |
| Charwat, V | 1 |
| Siemons, B | 1 |
| Finsberg, H | 1 |
| Miller, EW | 1 |
| Edwards, AG | 1 |
| Healy, KE | 1 |
| Ogah, OS | 1 |
| Umuerri, EM | 1 |
| Adebiyi, A | 1 |
| Orimolade, OA | 1 |
| Sani, MU | 1 |
| Ojji, DB | 1 |
| Mbakwem, AC | 1 |
| Stewart, S | 1 |
| Sliwa, K | 1 |
| Lo, CH | 2 |
| Wei, JC | 2 |
| Wang, YH | 2 |
| Tsai, CF | 2 |
| Chan, KC | 2 |
| Li, LC | 2 |
| Lo, TH | 2 |
| Su, CH | 2 |
| Smoke, SM | 1 |
| Leach, H | 1 |
| Leonida, N | 1 |
| Raja, K | 1 |
| Shah, M | 1 |
| Patel, V | 1 |
| Patel, G | 1 |
| Daniel, NM | 1 |
| Gerges, J | 1 |
| Patel, A | 1 |
| Faselis, C | 1 |
| Zeng-Treitler, Q | 1 |
| Cheng, Y | 1 |
| Kerr, GS | 1 |
| Nashel, DJ | 1 |
| Liappis, AP | 1 |
| Weintrob, AC | 1 |
| Karasik, PE | 1 |
| Arundel, C | 1 |
| Boehm, D | 1 |
| Heimall, MS | 1 |
| Connell, LB | 1 |
| Taub, DD | 1 |
| Shao, Y | 1 |
| Redd, DF | 1 |
| Sheriff, HM | 1 |
| Zhang, S | 1 |
| Fletcher, RD | 1 |
| Fonarow, GC | 1 |
| Moore, HJ | 1 |
| Ahmed, A | 1 |
| Keyhani, S | 1 |
| Kelly, JD | 1 |
| Bent, S | 1 |
| Boscardin, WJ | 1 |
| Shlipak, MG | 1 |
| Leonard, S | 1 |
| Abraham, A | 1 |
| Lum, E | 1 |
| Lau, N | 1 |
| Austin, C | 1 |
| Oldenburg, CE | 1 |
| Zillich, A | 1 |
| Lopez, L | 1 |
| Zhang, Y | 1 |
| Lietman, T | 1 |
| Bravata, DM | 1 |
| Hennekens, CH | 1 |
| Rane, M | 1 |
| Solano, J | 1 |
| Alter, S | 1 |
| Johnson, H | 1 |
| Krishnaswamy, S | 1 |
| Shih, R | 1 |
| Maki, D | 1 |
| DeMets, DL | 1 |
| Ten Broeke, R | 1 |
| Mestrom, E | 1 |
| Woo, L | 1 |
| Kreeftenberg, H | 1 |
| BURRELL, ZL | 1 |
| MARTINEZ, AC | 1 |
| ORTOLANI, G | 1 |
| GIULIANI, V | 1 |
| ELISEO, V | 1 |
| Yanturali, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Low-dose Hydroxychloroquine and Bromhexine: a Novel Regimen for COVID-19 Prophylaxis in Healthcare Professionals (ELEVATE Trial)[NCT04340349] | Early Phase 1 | 214 participants (Anticipated) | Interventional | 2021-02-01 | Enrolling by invitation | ||
| Safety and Efficacy of Post-exposure Prophylaxis With Hydroxychloroquine (HCQ) for the Prevention of COVID-19 in High-risk Older Individuals in Long-term and Specialized Care: A Double-blind Randomized Control Trial[NCT04397328] | Phase 3 | 336 participants (Anticipated) | Interventional | 2020-05-19 | Not yet recruiting | ||
| Trial of Early Therapies During Non-hospitalized Outpatient Window (TREAT NOW) for COVID-19[NCT04372628] | Phase 2 | 452 participants (Actual) | Interventional | 2020-06-01 | Completed | ||
| Efficacy and Safety of Antimicrobial Stewardship Intervention in Hospitalized COVID-19 Patients: A Pragmatic Clinical Trial[NCT04896866] | 833 participants (Actual) | Interventional | 2021-03-01 | Completed | |||
| The Safety and Efficacy Outcome of Ivermectin Plus Doxycycline in Treatment of RT-PCR Positive Adult Mild Covid-19 Cases: a Randomized Double Blind Placebo Controlled Trial[NCT04551755] | Phase 2 | 188 participants (Anticipated) | Interventional | 2020-09-30 | Not yet recruiting | ||
| Evaluation of a New Score Incorporating Endothelial Dysfunction for the Assessment of Coronary Heart Disease Risk in Patients With Rheumatoid Arthritis: a 3-year Prospective Study.[NCT02341066] | 3,000 participants (Anticipated) | Observational | 2015-07-31 | Recruiting | |||
| QT-Logs : a Clinical Study to Monitor Cardiac Safety, With Artificial Intelligence for QT Interval Analysis of ECG Data From Smartwatches, in Patients Receiving Hydroxychloroquine Treatment for COVID-19[NCT04371744] | 100 participants (Actual) | Observational [Patient Registry] | 2020-04-17 | Completed | |||
| VA Remote and Equitable Access to COVID-19 Healthcare Delivery (VA-REACH TRIAL)[NCT04363203] | Phase 3 | 300 participants (Anticipated) | Interventional | 2020-04-30 | Suspended (stopped due to concerns related to study drug) | ||
| Chloroquine for Patients With Symptomatic Persistent Atrial Fibrillation: A Prospective Pilot Study[NCT02932007] | Phase 2 | 40 participants (Anticipated) | Interventional | 2017-03-28 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Number of days without fever from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 16 |
| Placebo Control Group | 17 |
Number of days outside the hospital from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
Number of days outside the ICU from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
Number of Days without oxygen Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
Number of days from enrollment to hospitalization (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 6 |
| Placebo Control Group | 7 |
Number of days from enrollment to resolution of COVID-19 symptoms (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 11 |
| Placebo Control Group | 11 |
Number of vasopressor-free days through Study Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
Number of days without ventilator use from Day 1 to Day 29 (Group 2 and Placebo Control Group) (NCT04372628)
Timeframe: Day 1 to Day 29
| Intervention | days (Median) |
|---|---|
| Group 2 - Lopinavir/Ritonavir | 17 |
| Placebo Control Group | 17 |
12 reviews available for hydroxychloroquine and Arrhythmia
| Article | Year |
|---|---|
Arrhythmogenic Risk and Mechanisms of QT-Prolonging Drugs to Treat COVID-19.
Topics: Arrhythmias, Cardiac; Azithromycin; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Humans; | 2022 |
Considerations for Drug Interactions on QTc in Exploratory COVID-19 Treatment.
Topics: Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug | 2020 |
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infe | 2020 |
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infe | 2020 |
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infe | 2020 |
Safety considerations with chloroquine, hydroxychloroquine and azithromycin in the management of SARS-CoV-2 infection.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroquine; Coronavirus Infe | 2020 |
Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol.
Topics: Anti-Bacterial Agents; Antibodies, Monoclonal; Antimalarials; Arrhythmias, Cardiac; Betacoronavirus; | 2020 |
Recommendations for the measurement of the QT interval during the use of drugs for COVID-19 infection treatment. Updatable in accordance with the availability of new evidence.
Topics: Adult; Aged; Antimalarials; Arrhythmias, Cardiac; Azithromycin; Chloroquine; Coronavirus Infections; | 2020 |
Approach to Acute Cardiovascular Complications in COVID-19 Infection.
Topics: Acute Coronary Syndrome; Anti-Bacterial Agents; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin | 2020 |
Prophylactic (hydroxy)chloroquine in COVID-19: Potential relevance for cardiac arrhythmia risk.
Topics: Antimalarials; Arrhythmias, Cardiac; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Dru | 2020 |
Hydroxychloroquine in COVID-19 Therapy: Protection Versus Proarrhythmia.
Topics: Arrhythmias, Cardiac; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Hu | 2020 |
Existing highly accumulating lysosomotropic drugs with potential for repurposing to target COVID-19.
Topics: Anti-Inflammatory Agents; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Che | 2020 |
COVID-19 and the burning issue of drug interaction: never forget the ECG.
Topics: Adenosine Monophosphate; Alanine; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiviral | 2021 |
Incidence and treatment of arrhythmias secondary to coronavirus infection in humans: A systematic review.
Topics: Anti-Arrhythmia Agents; Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Atrial Fibrillat | 2021 |
SARS-CoV 2 Infection (Covid-19) and Cardiovascular Disease in Africa: Health Care and Socio-Economic Implications.
Topics: Acute Coronary Syndrome; Africa; Antimalarials; Arrhythmias, Cardiac; Cardiovascular Diseases; Chlor | 2021 |
46 other studies available for hydroxychloroquine and Arrhythmia
| Article | Year |
|---|---|
Assessment of proarrhythmogenic risk for chloroquine and hydroxychloroquine using the CiPA concept.
Topics: Action Potentials; Antiviral Agents; Arrhythmias, Cardiac; Biological Assay; Chloroquine; Computer S | 2021 |
In vitro ion channel profile and ex vivo cardiac electrophysiology properties of the R(-) and S(+) enantiomers of hydroxychloroquine.
Topics: Action Potentials; Animals; Antimalarials; Arrhythmias, Cardiac; Electrocardiography; Electrophysiol | 2022 |
Comparing Outcomes of Two Antiviral Therapy Combinations among COVID-19 Patients.
Topics: Aged; Antiviral Agents; Arrhythmias, Cardiac; Atazanavir Sulfate; Bilirubin; COVID-19; COVID-19 Drug | 2022 |
Arrhythmogenic mechanisms of interleukin-6 combination with hydroxychloroquine and azithromycin in inflammatory diseases.
Topics: Animals; Antibodies, Monoclonal, Humanized; Arrhythmias, Cardiac; Azithromycin; COVID-19; COVID-19 D | 2022 |
Hydroxychloroquine: Heart-Throb No More?
Topics: Antirheumatic Agents; Arrhythmias, Cardiac; Arthritis, Rheumatoid; Drug Therapy, Combination; Humans | 2022 |
An observational, retrospective, comprehensive pharmacovigilance analysis of hydroxychloroquine-associated cardiovascular adverse events in patients with and without COVID-19.
Topics: Arrhythmias, Cardiac; Bradycardia; Cardiac Conduction System Disease; Cardiovascular System; COVID-1 | 2022 |
Hydroxychloroquine-Associated Cardiomyopathy With Midmyocardial Right Ventricular Tachycardia.
Topics: Arrhythmias, Cardiac; Cardiomyopathies; Heart Ventricles; Humans; Hydroxychloroquine; Tachycardia, V | 2022 |
Hydroxychloroquine-Associated Cardiomyopathy With Midmyocardial Right Ventricular Tachycardia.
Topics: Arrhythmias, Cardiac; Cardiomyopathies; Heart Ventricles; Humans; Hydroxychloroquine; Tachycardia, V | 2022 |
Hydroxychloroquine-Associated Cardiomyopathy With Midmyocardial Right Ventricular Tachycardia.
Topics: Arrhythmias, Cardiac; Cardiomyopathies; Heart Ventricles; Humans; Hydroxychloroquine; Tachycardia, V | 2022 |
Hydroxychloroquine-Associated Cardiomyopathy With Midmyocardial Right Ventricular Tachycardia.
Topics: Arrhythmias, Cardiac; Cardiomyopathies; Heart Ventricles; Humans; Hydroxychloroquine; Tachycardia, V | 2022 |
Hydroxychloroquine-Associated Cardiomyopathy With Midmyocardial Right Ventricular Tachycardia.
Topics: Arrhythmias, Cardiac; Cardiomyopathies; Heart Ventricles; Humans; Hydroxychloroquine; Tachycardia, V | 2022 |
Hydroxychloroquine-Associated Cardiomyopathy With Midmyocardial Right Ventricular Tachycardia.
Topics: Arrhythmias, Cardiac; Cardiomyopathies; Heart Ventricles; Humans; Hydroxychloroquine; Tachycardia, V | 2022 |
Hydroxychloroquine-Associated Cardiomyopathy With Midmyocardial Right Ventricular Tachycardia.
Topics: Arrhythmias, Cardiac; Cardiomyopathies; Heart Ventricles; Humans; Hydroxychloroquine; Tachycardia, V | 2022 |
Hydroxychloroquine-Associated Cardiomyopathy With Midmyocardial Right Ventricular Tachycardia.
Topics: Arrhythmias, Cardiac; Cardiomyopathies; Heart Ventricles; Humans; Hydroxychloroquine; Tachycardia, V | 2022 |
Hydroxychloroquine-Associated Cardiomyopathy With Midmyocardial Right Ventricular Tachycardia.
Topics: Arrhythmias, Cardiac; Cardiomyopathies; Heart Ventricles; Humans; Hydroxychloroquine; Tachycardia, V | 2022 |
Risk of arrhythmia among new users of hydroxychloroquine: comment on the article by Hoque et al.
Topics: Antirheumatic Agents; Arrhythmias, Cardiac; Humans; Hydroxychloroquine | 2023 |
Real-Life Data on Hydroxychloroquine or Chloroquine with or Without Azithromycin in COVID-19 Patients: A Retrospective Analysis in Brazil.
Topics: Aged; Arrhythmias, Cardiac; Azithromycin; Brazil; Chloroquine; Cohort Studies; COVID-19; COVID-19 Dr | 2023 |
Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Canada; Coronavirus Infection | 2020 |
Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Canada; Coronavirus Infection | 2020 |
Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Canada; Coronavirus Infection | 2020 |
Guidance on Minimizing Risk of Drug-Induced Ventricular Arrhythmia During Treatment of COVID-19: A Statement from the Canadian Heart Rhythm Society.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Canada; Coronavirus Infection | 2020 |
COVID-19, Chloroquine Repurposing, and Cardiac Safety Concern: Chirality Might Help.
Topics: Antimalarials; Antiviral Agents; Arrhythmias, Cardiac; Betacoronavirus; Cardiotoxicity; Chloroquine; | 2020 |
Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated With Hydroxychloroquine and/or Azithromycin.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID | 2020 |
Effect of Chloroquine, Hydroxychloroquine, and Azithromycin on the Corrected QT Interval in Patients With SARS-CoV-2 Infection.
Topics: Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Chloroqui | 2020 |
QTc evaluation in COVID-19 patients treated with chloroquine/hydroxychloroquine.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Cardiotoxicity; Chloroquine; Coronavirus Infec | 2020 |
Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State.
Topics: Adolescent; Adult; Aged; Anti-Infective Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; | 2020 |
Emerging cardiological issues during the COVID-19 pandemic.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Betacoronavirus; Coronary Artery Disease; Coronavirus Infect | 2020 |
Response to: 'Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?' by Erre
Topics: Antimalarials; Arrhythmias, Cardiac; COVID-19; Humans; Hydroxychloroquine; Inflammation; Rheumatic D | 2021 |
Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?
Topics: Antimalarials; Antirheumatic Agents; Arrhythmias, Cardiac; COVID-19; Humans; Hydroxychloroquine; Inf | 2021 |
The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin.
Topics: Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Coronavirus Infections; COVID-19; Electrocardio | 2020 |
The pandemic's first major research scandal erupts.
Topics: Antimalarials; Arrhythmias, Cardiac; Clinical Trials as Topic; Coronavirus Infections; COVID-19; Dat | 2020 |
Potential pro-arrhythmic effects of pharmacotherapy against SARS-CoV-2.
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Chloroquine; Coronavirus Infections; COVID-19; | 2020 |
Incidence of arrhythmias and electrocardiographic abnormalities in symptomatic pediatric patients with PCR-positive SARS-CoV-2 infection, including drug-induced changes in the corrected QT interval.
Topics: Anti-Infective Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Child; Clinical Laborato | 2020 |
Low hospitalization rate without severe arrhythmias: a prospective survey on 350 patients early home treated with hydroxychloroquine during COVID-19 pandemic.
Topics: Anti-Infective Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronavirus; Clinical Laboratory Tech | 2020 |
Acute QT Interval Modifications During Hydroxychloroquine-Azithromycin Treatment in the Context of COVID-19 Infection.
Topics: Adult; Aged; Aged, 80 and over; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Betacoronaviru | 2020 |
Reply to: "QT prolongation with hydroxychloroquine and azithromycin for the treatment of COVID-19: The need for pharmacogenetic insights".
Topics: Arrhythmias, Cardiac; Azithromycin; COVID-19; Humans; Hydroxychloroquine; Pandemics; Pharmacogenetic | 2020 |
Temporal Trends in Arrhythmogenicity Related to Treatment of COVID-19 Infection.
Topics: Action Potentials; Aged; Antiviral Agents; Arrhythmias, Cardiac; Cardiotoxicity; Coronavirus Infecti | 2020 |
Arrhythmic safety of hydroxychloroquine in COVID-19 patients from different clinical settings.
Topics: Arrhythmias, Cardiac; COVID-19; COVID-19 Drug Treatment; Electrocardiography; Female; Humans; Hydrox | 2020 |
Has the door closed on hydroxychloroquine for SARS-COV-2?
Topics: Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Cardiotoxicity; COVID-19 Drug Treatment; Drug | 2021 |
It is time to drop hydroxychloroquine from our COVID-19 armamentarium.
Topics: Animals; Antiviral Agents; Arrhythmias, Cardiac; Azithromycin; Bradycardia; COVID-19 Drug Treatment; | 2020 |
COVID-19 and Cardiac Concerns for Psychiatric Patients.
Topics: Antidepressive Agents; Antiviral Agents; Arrhythmias, Cardiac; Atrial Fibrillation; Atrioventricular | 2020 |
Hydroxychloroquine/azithromycin treatment, QT interval and ventricular arrhythmias in hospitalised patients with COVID-19.
Topics: Adult; Aged; Anti-Bacterial Agents; Arrhythmias, Cardiac; Azithromycin; Comorbidity; COVID-19; COVID | 2021 |
Smartwatch Electrocardiogram and Artificial Intelligence for Assessing Cardiac-Rhythm Safety of Drug Therapy in the COVID-19 Pandemic. The QT-logs study.
Topics: Adult; Arrhythmias, Cardiac; Artificial Intelligence; Azithromycin; COVID-19 Drug Treatment; Electro | 2021 |
Cardiac arrhythmias in COVID-19 patients: A combination of viral comorbidities and pro-arrhythmic drug interactions.
Topics: Angiotensin-Converting Enzyme 2; Anti-Bacterial Agents; Antimalarials; Arrhythmias, Cardiac; Azithro | 2021 |
Applying the CiPA approach to evaluate cardiac proarrhythmia risk of some antimalarials used off-label in the first wave of COVID-19.
Topics: Animals; Antimalarials; Arrhythmias, Cardiac; Chloroquine; CHO Cells; COVID-19 Drug Treatment; Crice | 2021 |
Effect of Hydroxychloroquine and Azithromycin on QT Interval Prolongation and Other Cardiac Arrhythmias in COVID-19 Confirmed Patients.
Topics: Adult; Aged; Arrhythmias, Cardiac; Azithromycin; COVID-19 Drug Treatment; Electrocardiography; Femal | 2021 |
In vitro safety "clinical trial" of the cardiac liability of drug polytherapy.
Topics: Arrhythmias, Cardiac; Azithromycin; Cardiotoxicity; Clinical Trials as Topic; COVID-19 Drug Treatmen | 2021 |
Hydroxychloroquine Does Not Increase the Risk of Cardiac Arrhythmia in Common Rheumatic Diseases: A Nationwide Population-Based Cohort Study.
Topics: Antirheumatic Agents; Arrhythmias, Cardiac; Cohort Studies; Female; Humans; Hydroxychloroquine; Inci | 2021 |
Medication safety in a pandemic: A multicentre point prevalence study of QTc monitoring of hydroxychloroquine for COVID-19.
Topics: Arrhythmias, Cardiac; COVID-19 Drug Treatment; Electrocardiography; Enzyme Inhibitors; Female; Human | 2021 |
Cardiovascular Safety of Hydroxychloroquine in US Veterans With Rheumatoid Arthritis.
Topics: Aged; Antirheumatic Agents; Arrhythmias, Cardiac; Arthritis, Rheumatoid; Female; Humans; Hydroxychlo | 2021 |
A telehealth-based randomized controlled trial: A model for outpatient trials of off-label medications during the COVID-19 pandemic.
Topics: Ambulatory Care; Anti-Bacterial Agents; Arrhythmias, Cardiac; Azithromycin; COVID-19 Drug Treatment; | 2021 |
Association of hydroxychloroquine and cardiac arrhythmia in patients with systemic lupus erythematosus: A population-based case control study.
Topics: Antirheumatic Agents; Arrhythmias, Cardiac; Female; Humans; Hydroxychloroquine; Lupus Erythematosus, | 2021 |
Updates on Hydroxychloroquine in Prevention and Treatment of COVID-19.
Topics: Antimalarials; Arrhythmias, Cardiac; Chemoprevention; COVID-19; COVID-19 Drug Treatment; Humans; Hyd | 2022 |
Early treatment with intravenous lipid emulsion in a potentially lethal hydroxychloroquine intoxication.
Topics: Adult; Arrhythmias, Cardiac; Chromatography, Liquid; Drug Overdose; Electrocardiography; Fat Emulsio | 2016 |
Chloroquine and hydroxychloroquine in the treatment of cardiac arrhythmias.
Topics: Arrhythmias, Cardiac; Chloroquine; Humans; Hydroxychloroquine | 1958 |
[Chloroquine and hydroxychloroquine in the therapy of arrhythmia due to fibrillation].
Topics: Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Conduction System Disease; Chloroquine; Heart Conduc | 1963 |
Diazepam for treatment of massive chloroquine intoxication.
Topics: Arrhythmias, Cardiac; Cardiovascular Agents; Diazepam; Drug Overdose; Female; Humans; Hydroxychloroq | 2004 |